Qiagen NV
NYSE:QGEN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
39.23
47.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Qiagen NV
Qiagen NV
Cost of Revenue
Qiagen NV
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Qiagen NV
NYSE:QGEN
|
Cost of Revenue
-$732.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
Qiagen NV
Glance View
Qiagen NV is a leading global provider of sample and assay technologies that empower researchers and healthcare professionals in their quest for answers in genomics and molecular biology. Founded in 1984 and headquartered in Hilden, Germany, the company has established a formidable presence in the biotechnology sector, offering innovative solutions that facilitate the detection of diseases, genetic research, and drug development. Qiagen’s diverse portfolio spans from nucleic acid extraction kits to molecular diagnostic tests, catering to both academic research institutions and clinical settings. This extensive product range not only supports the growing demand for precision medicine but also aligns with global health trends emphasizing personalized treatments based on genetic insights. For investors, Qiagen presents an appealing opportunity as it operates in a lucrative market characterized by robust growth prospects. The company has consistently demonstrated its ability to adapt to changing healthcare landscapes, evidenced by its strategic focus on expanding offerings in molecular diagnostics and companion diagnostics, which underpin the future of targeted therapies. Additionally, Qiagen's commitment to innovation is underscored by significant investments in research and development, positioning it well to capitalize on advances in the rapidly evolving life sciences market. With a strong financial track record and a commitment to enhancing shareholder value through strategic partnerships and acquisitions, Qiagen is not just a participant in the biotech ecosystem; it is a leader steering the course for future advancements in health and research.
See Also
What is Qiagen NV's Cost of Revenue?
Cost of Revenue
-732.8m
USD
Based on the financial report for Sep 30, 2024, Qiagen NV's Cost of Revenue amounts to -732.8m USD.
What is Qiagen NV's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-5%
Over the last year, the Cost of Revenue growth was -2%. The average annual Cost of Revenue growth rates for Qiagen NV have been 2% over the past three years , -7% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet
